# SynOmix Version Comparison: v6.0 â†’ v7.0

## Summary

| Aspect | v6.0 | v7.0 |
|--------|------|------|
| Cancer Types | 3 | **7** (+4) |
| Drug Targets | 0 | **21** |
| Survival Analysis | âŒ | âœ… |
| Cell Deconvolution | âœ… | âœ… |

## New Features in v7.0

### 1. Survival Analysis
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ“ˆ Prognostic Analysis             â”‚
â”‚                                    â”‚
â”‚ Risk Score: 65%                    â”‚
â”‚ Risk Group: Intermediate-High      â”‚
â”‚ 5-Year Survival: 50-70%            â”‚
â”‚                                    â”‚
â”‚ âš  High proliferation               â”‚
â”‚ âš  TP53 mutation                    â”‚
â”‚ âœ“ High immune response             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 2. Drug Recommendations
```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚ ğŸ’Š Actionable Drug Targets         â”‚
â”‚                                    â”‚
â”‚ ERBB2 - High expression   FDA âœ“   â”‚
â”‚ â€¢ Trastuzumab                      â”‚
â”‚ â€¢ Pertuzumab                       â”‚
â”‚                                    â”‚
â”‚ PIK3CA - Mutated (15%)    FDA âœ“   â”‚
â”‚ â€¢ Alpelisib                        â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

### 3. New Cancer Types

| Cancer | Subtypes Added |
|--------|---------------|
| Prostate | Luminal, Basal, Neuroendocrine |
| Ovarian | HG Serous, LG Serous, Clear Cell |
| Pancreatic | Classical, Basal-like, MSI-H |
| Melanoma | BRAF, NRAS, Triple WT |

### 4. Start Over Button
- One-click reset to upload new data
- No page refresh needed

## Clinical Workflow (v7.0)
```
Upload Data â†’ Subtype Prediction â†’ Microenvironment
     â†“              â†“                    â†“
  5 layers    Confidence %         Cell composition
                   â†“                    â†“
           Survival Analysis â†’ Drug Recommendations
                   â†“                    â†“
             Risk group          FDA-approved Rx
```

---
*Generated: December 25, 2025*
